Metropolis Healthcare

Metropolis Healthcare delivered a strong FY26 with group revenue of ₹1,646 croreCurrent reported value: ₹1,646 crore. No comparable prior figure is available in the source record. (+23.6Current reported value: 23.6. No comparable prior figure is available in the source record.% YoY) and EBITDA margin of 24.4%Current reported value: 24.4%. No comparable prior figure is available in the source record.. Organic revenue grew 13.7%Current reported value: 13.7%. No comparable prior figure is available in the source record. YoY, exceeding the 12-13% guidance, driven by patient volume growth of 7.5%Current 5%. Reported change: +5% YoY. and realization improvement. Organic EBITDA margin expanded 140 bpsCurrent reported value: 140 bps. No comparable prior figure is available in the source record. to 25.9%, aided by lab platform upgrades, vendor consolidation, and operating leverage. The core diagnostics acquisition achieved high single-digit EBITDA margin within four quarters, on track for 20%+ in three years. Management guided for 14-15% organic revenue growth and 27-28% group EBITDA margin over the next three years, supported by network productivity gains, specialty mix improvement, and digital channel expansion. Key risks include competitive intensity in tier-1 cities and potential integration challenges from future M&A.